Thor Explorations, IXICO, EMV Capital, Empire Metals, Coiled Therapeutics - Small Cap Snapshot

Why It Matters

The announcements could drive significant upside for investors seeking diversified exposure to commodities, emerging biotech, and growth‑stage small caps, while highlighting sectors benefiting from macro trends.

Key Takeaways

• Thor Explorations Q1 revenue $74.3M, net income $46.7M.
• Thor targets 75k‑85k ounces gold production this year.
• EMV Capital AUM up 14% to £112.5M, losses cut 83%.
• Empire Metals sells 75% stake for AU$750B, focuses on Pitfield titanium.
• Coil Therapeutics launches OTCQB listing, cites 80% clinical benefit.

Summary

Proactive’s Tuesday small‑cap roundup highlighted five companies—Thor Explorations, Execo, EMV Capital, Empire Metals and Coil Therapeutics—each reporting material developments that could reshape their market positioning.

Thor posted Q1 revenue of $74.3 million and net income of $46.7 million, buoyed by a gold price above $4,800 per ounce and a production target of 75,000‑85,000 ounces for 2024. Execo forecast at least 15% revenue growth after a 23% first‑half increase and a £10 million raise to accelerate its tech‑bio strategy. EMV Capital grew assets under management 14% to £112.5 million while cutting losses 83% to £600 k.

Empire Metals signed a definitive agreement to sell its 75% stake in a non‑core gold asset for AU$750 billion, redirecting capital to the Pitfield titanium project, which holds a 2.2‑billion‑ton resource at 5.1% TiO₂. Coil Therapeutics began trading on the OTCQB, with CEO Sridhar Vempathi touting an 80% clinical‑benefit rate and labeling 2026 a transformational year.

These moves signal heightened capital allocation toward high‑margin commodities and late‑stage biotech, offering investors exposure to rising gold prices, a world‑class titanium discovery, and potential oncology breakthroughs.

Original Description

Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF, FRA:T2X) delivered a strong first quarter, with revenue up to $74.3 million and net income rising to $46.7 million as a gold price of $4,820 per ounce more than offset lower sales volumes. The company is on track for 75,000 to 85,000 ounces of production this year and is advancing toward a final investment decision at its Douta project in Senegal.

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) is guiding for at least 15% revenue growth this year after a strong first half, with revenue up 23% and its order book growing 38% to £18.1 million. A £10 million fundraise will accelerate the company's TechBio strategy, including a partnership with Medidata, whose platform is used in 80% of FDA novel drug approvals.

EMV Capital (AIM:EMVC, FRA:NTK1) grew assets under management 14% to £112.5 million in 2025, with group losses falling 83% to £0.6 million as revenue rose 17%. CEO Dr Ilian Iliev says the group is increasingly optimistic as portfolio companies approach key commercial and regulatory milestones.

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has signed a definitive agreement to sell its 75% stake in a non-core gold asset near Kalgoorlie for A$750,000, freeing up capital and management focus for the Pitfield Titanium Project. Pitfield has a mineral resource of 2.2 billion tonnes grading 5.1% TiO₂, making it one of the largest titanium discoveries globally.

Coiled Therapeutics (AIM:COIL) has begun trading on the US OTCQB market under the ticker COTXF, giving American investors dollar-denominated access to the oncology company's shares. CEO Sridhar Vempati says 2026 will be "a transformational year," with recent clinical data from its ongoing trial showing an 80% clinical benefit rate.

Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.